Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectally administered micronized progesterone for luteal phase support in HRT-FET cycle
2023-504616-15-00Phase 3Withdrawn
- Sponsor
- Central Denmark Region
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of progesterone in infertility (2 arms), sponsored by Central Denmark Region. Primary endpoint: Ongoing pregnancy rate at 12 weeks after HRT-FET with rectally administered progesterone only. Planned start Jun 2023; status: withdrawn.
02
Drugs
progesterone
03
Conditions
infertility
Beyond the preview
Go deeper on 2023-504616-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504616-15-00.